6 days Ago By Defense World Staff
Alliancebernstein L.P. grew its stake in uniQure (NASDAQ:QURE – Free Report) by 14.
2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 203,919 shares of the biotechnology company’s stock after purchasing an additional 25,319 shares during the quarter. Alliancebernstein L.
P. owned about 0.42% of uniQure worth $3,601,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd.
raised its stake in uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co.
Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after buying an additional 969 shares during the period. Twin Tree Management LP bought a new stake in shares of uniQure in the fourth quarter worth about $77,000.
FNY Investment Advisers LLC acquired a new stake in shares of uniQure during the fourth quarter worth about $88,000. Geode Capital Management LLC lifted its holdings in shares of uniQure by 1.3% during the 3rd quarter.
Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after purchasing an additional 6,362 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in uniQure by 6.
3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock valued at $1,367,000 after acquiring an additional 16,464 shares in the last quarter.
78.83% of the stock is currently owned by institutional investors. uniQure Trading Up 2.
7 %Shares of uniQure stock opened at $9.17 on Tuesday. The company has a market capitalization of $495.
89 million, a P/E ratio of -1.85 and a beta of 0.42.
The stock has a fifty day simple moving average of $12.14 and a 200 day simple moving average of $11.14.
uniQure has a 12-month low of $3.73 and a 12-month high of $19.18.
The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.
92. Analyst Ratings ChangesSeveral brokerages have commented on QURE. HC Wainwright reissued a “buy” rating and set a $70.
00 price target on shares of uniQure in a research report on Tuesday, March 4th. Mizuho upped their price objective on uniQure from $7.00 to $20.
00 and gave the company a “neutral” rating in a report on Thursday, December 19th. Stifel Nicolaus increased their target price on shares of uniQure from $12.00 to $32.
00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Wells Fargo & Company reduced their price target on shares of uniQure from $35.00 to $30.
00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. Finally, StockNews.com raised uniQure to a “sell” rating in a research note on Tuesday, March 11th.
One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.
80.View Our Latest Stock Report on uniQureInsiders Place Their BetsIn other news, CFO Christian Klemt sold 14,341 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $10.
70, for a total value of $153,448.70. Following the transaction, the chief financial officer now owns 152,372 shares in the company, valued at $1,630,380.
40. The trade was a 8.60 % decrease in their position.
The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 28,341 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th.
The shares were sold at an average price of $10.29, for a total value of $291,628.89.
Following the completion of the transaction, the chief executive officer now directly owns 651,454 shares of the company’s stock, valued at approximately $6,703,461.66. This represents a 4.
17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock valued at $961,401 in the last three months.
4.74% of the stock is currently owned by insiders. uniQure Profile (Free Report)uniQure N.
V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B.
The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.See AlsoFive stocks we like better than uniQureStock Market Sectors: What Are They and How Many Are There? Why NVIDIA Stock Could Soar Despite Wall Street DowngradesWhat is the Australian Securities Exchange (ASX) Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldHow to Read Stock Charts for Beginners3 Hot New IPOs Defying the 2025 Market Slump.
